Please login to the form below

Not currently logged in
Email:
Password:

Shares in Mannkind drop on inhaleable insulin sales decrease

US-based pharma start-up Mannkind witnesses a 16 per cent fall in its share value after news that it was depleting its cash reserves and had no new investors in the pipeline

US-based pharmaceutical start-up Mannkind witnessed a 16 per cent fall in its share value after news that it was depleting its cash reserves and had no new investors in the pipeline.

Shares in the company fell USD 1.73 to bottom out at USD 8.87, the lowest value for two years.

Mannkind, which is developing an inhaled form of insulin, has also postponed its earnings report, according to CFO Richard L Anderson, who is set to retire by the end of 2008. The results have been scheduled to be released on 9 August.

The company's CEO, Hakan Edstrom, stressed that Anderson's departure was not a sign that the CFO had lost confidence in the company. He tried to counter poor share performance by saying: "We are very much on our timeline for bringing the new insulin drug, Technosphere, to market."

Edstrom added that MannKind was planning to seek approval for the medication from the FDA by the end of 2008. The company has spent more than USD 700m developing Technosphere, which it hopes will make headway into the USD 21bn insulin market.

MannKind had been seeking a financial partner to infuse new money into the venture. But the funds did not materialise because potential investors want to see further results from Technosphere's ongoing clinical trials. Other factors in the lack of investment include the poor sales performance of Pfizer's Exubera, an inhaled form of insulin already on the market. MannKind says Technosphere, which comes in a smaller packet than the Pfizer drug, will be more effective and easier to use.

Company founder and chairman, billionaire Alfred E Mann, has already extended a USD 150m credit line to MannKind, which offers the company a cash buffer while it looks for more funding.

Cash reserves at Mannkind were down to USD 284m by the end of June 2007 from USD 365.6m in Q1 FY07 and USD 436.5m in Q4 FY06.

Wachovia analysts maintained their "Market Outperform" rating for the firm on 3 August.

7th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics